Christin E Burd, PhD

College

College of Arts & Sciences

Department/Division

Molecular Genetics

Academic Title

Asst Professor

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

>Cancer ● Melanoma ● DNA Damage ● Lymphoma, Primary Effusion ● Body Mass Index

Christin Burd, PhD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where she focuses her research on improving our understanding of the connections between cancer and aging.

Her team’s goal is to bridge bench science and clinical trials. In particular, she aims to improve methods to prevent, diagnose and treat melanoma. Recent work from her lab examines how aging of the immune system is impacted by different cancer therapies and may influence drug toxicity and patient outcomes.

Dr. Burd has developed several state-of-the-art genetically engineered models which allow scientists to track the formation and progression of spontaneous cancers and test melanoma prevention strategies. She was the first in Ohio to receive a prestigious Damon Runyon-Rachleff Innovation Award. This award funds Dr. Burd’s ongoing research to develop new models and methods to combat tumors with a RAS gene mutation.

Dr. Burd’s work is featured in numerous well-respected journals, including Cell, Nature Medicine, Cancer Discovery, Pigment Cell & Melanoma Research and Molecular Cancer Research.

Office Location

Biomedical Research Tower

460 W 12th Ave, Columbus, OH 43210

614-688-7569

614-688-4245

burd.25@osu.edu;CHRISTIN.BURD@OSUMC.EDU

Publications

Mouse Models of Accelerated Cellular Senescence.

Yousefzadeh MJ, Melos KI, Angelini L, Burd CE, Robbins PD, Niedernhofer LJ

Methods Mol Biol 1896 203-230 01/01/2019
Fisetin is a senotherapeutic that extends health and lifespan.

Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, Kirkland JL, Robbins PD, Niedernhofer LJ

EBioMedicine 36 18-28 10/01/2018
Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE

J Geriatr Oncol in press 07/05/2018
Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.

LaPak KM, Vroom DC, Garg AA, Guan X, Hays JL, Song JW, Burd CE

Oncotarget 9 25386-25401 05/22/2018
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J

EMBO Mol Med 10 01/01/2018
Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.

Robinson AR, Yousefzadeh MJ, Rozgaja TA, Wang J, Li X, Tilstra JS, Feldman CH, Gregg SQ, Johnson CH, Skoda EM, Frantz MC, Bell-Temin H, Pope-Varsalona H, Gurkar AU, Nasto LA, Robinson RAS, Fuhrmann-Stroissnigg H, Czerwinska J, McGowan SJ, Cantu-Medellin N, Harris JB, Maniar S, Ross MA, Trussoni CE, LaRusso NF, Cifuentes-Pagano E, Pagano PJ, Tudek B, Vo NV, Rigatti LH, Opresko PL, Stolz DB, Watkins SC, Burd CE, Croix CMS, Siuzdak G, Yates NA, Robbins PD, Wang Y, Wipf P, Kelley EE, Niedernhofer LJ

Redox Biol 17 259-273 01/01/2018
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB

Mol Cancer Ther 16 417-427 01/01/2017
Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.

Hennessey RC, Holderbaum AM, Bonilla A, Delaney C, Gillahan JE, Tober KL, Oberyszyn TM, Zippin JH, Burd CE

Pigment Cell Melanoma Res 30 477-487 01/01/2017
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

Guan X, LaPak KM, Hennessey RC, Yu CY, Shakya R, Zhang J, Burd CE

Mol Cancer Res 15 237-249 01/01/2017
Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.

Burd CE, Gill MS, Niedernhofer LJ, Robbins PD, Austad SN, Barzilai N, Kirkland JL

J Gerontol A Biol Sci Med Sci 71 1388-1394 01/01/2016
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE

Nat Med 22 632-40 01/01/2016
Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE

Bone Marrow Transplant 50 1379-81 10/01/2015
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, Fu K, Martin BL, Jeck WR, Souroullas GP, Darr DB, Zedek DC, Miley MJ, Baguley BC, Campbell SL, Sharpless NE

Cancer Discov 4 1418-29 12/01/2014
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, Sharpless NE

Pigment Cell Melanoma Res 27 653-63 07/01/2014

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Christin E Burd, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Mouse Models of Accelerated Cellular Senescence.

Fisetin is a senotherapeutic that extends health and lifespan.

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

Barriers to the Preclinical Development of Therapeutics that Target Aging Mechanisms.

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Christin E Burd, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication